Specifications of predominant nonserious adverse effects 4 weeks after intrathecal gadobutrol in various dosesa
| iNPH Cohort | Non-iNPH Cohort | ||||
|---|---|---|---|---|---|
| 0.50 mmol (n = 20) | 0.25 mmol (n = 86) | 0.10 mmol (n = 28) | 0.50 mmol (n = 34) | 0.25 mmol (n = 15) | |
| No adverse events (No.) (%) | 19 (95.0%) | 82 (95.3%) | 27 (96.4%) | 33 (97.1%) | 13 (86.7%) |
| Adverse events present (No.) (%) | 1 (5.0%) | 4 (4.7%) | 1 (3.6%) | 1 (2.9%) | 2 (13.3%) |
| Predominant adverse events | |||||
| Mild headache, nausea, and/or dizziness (No.) (%) | 1 (5.0%) | 2 (2.3%) | 1 (3.6%) | 0 | 1 (6.7%) |
| Moderate headache, nausea, and/or dizziness (No.) (%) | 0 | 2 (2.3%) | 0 | 0 | 0 |
| Severe headache, nausea, and/or dizziness (No.) (%) | 0 | 0 | 0 | 0 | 0 |
| Back pain from spinal puncture (No.) (%) | 0 | 0 | 0 | 0 | 1 (6.7%) |
| Other (No.) (%) | 0 | 0 | 0 | 1 (2.9%) | 0 |
↵a Data are given as numbers (percentages are in parentheses). The Pearson χ2 test showed no statistical differences between groups.